Non-Current Liabilities
Contract Liabilities, Non-Current
Regeneron Pharmaceuticals Contract Liabilities, Non-Current increased by 7.9% to $225.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.3%, from $211.80M to $225.10M. Over 5 years (FY 2020 to FY 2025), Contract Liabilities, Non-Current shows an upward trend with a 29.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
First reportedQ4 2017
Last reportedQ1 2026Apr 29, 2026
Metric ID:
contract_liabilities_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $50.70M | $56.50M | $73.30M | $33.50M | $58.70M | $60.10M | $69.80M | $85.50M | $116.20M | $125.30M | $126.70M | $185.80M | $205.60M | $207.40M | $185.70M | $211.80M | $206.30M | $219.20M | $208.70M | $225.10M |
| QoQ Change | — | +11.4% | +29.7% | -54.3% | +75.2% | +2.4% | +16.1% | +22.5% | +35.9% | +7.8% | +1.1% | +46.6% | +10.7% | +0.9% | -10.5% | +14.1% | -2.6% | +6.3% | -4.8% | +7.9% |
| YoY Change | — | — | — | — | +15.8% | +6.4% | -4.8% | +155.2% | +98.0% | +108.5% | +81.5% | +117.3% | +76.9% | +65.5% | +46.6% | +14.0% | +0.3% | +5.7% | +12.4% | +6.3% |
Range$33.50M – $225.10M
CAGR+36.9%
Avg YoY Growth+50.3%
Median YoY Growth+31.2%
Contract Liabilities, Non-Current at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's contract liabilities, non-current?
- Regeneron Pharmaceuticals (REGN) reported contract liabilities, non-current of $225.10M in Q1 2026.
- How has Regeneron Pharmaceuticals's contract liabilities, non-current changed year-over-year?
- Regeneron Pharmaceuticals's contract liabilities, non-current increased by 6.3% year-over-year, from $211.80M to $225.10M.
- What is the long-term trend for Regeneron Pharmaceuticals's contract liabilities, non-current?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's contract liabilities, non-current has grown at a 29.3% compound annual growth rate (CAGR), from $57.80M to $208.70M.